Silence Therapeutics
SLN
72 hedge funds and large institutions have $239M invested in Silence Therapeutics in 2026 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 4 closing their positions.
1,596% more call options, than puts
Call options by funds: $7.04M | Put options by funds: $415K
400% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 4
134% more capital invested
Capital invested by funds: $102M → $239M (+$137M)
29% more funds holding
Funds holding: 56 → 72 (+16)
11% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 19
4.93% more ownership
Funds ownership: 42.15% → 47.08% (+4.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$4.43M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.3M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$2.81M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.6M |
| 5 |
Morgan Stanley
New York
|
+$2.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$5.63M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.01M |
| 3 |
SG Americas Securities
New York
|
-$1.93M |
| 4 |
JHC
Jones Hill Capital
New York
|
-$1.59M |
| 5 |
Millennium Management
New York
|
-$1.16M |
SLN Hedge Fund Activity: Q2 2026 in Review
72 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q2 2026, worth a combined $239M — up 134% from $102M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new SLN positions and 4 closed out — a net gain of 16 holders — while 21 added to existing stakes and 19 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $4.43M. The largest seller was Nantahala Capital Management, cutting an estimated $5.63M.
- 72 institutional investors held Silence Therapeutics (SLN) as of Q2 2026, up from 56 in Q1 2026.
- Funds reported $239M of Silence Therapeutics stock for Q2 2026, up 134% quarter-over-quarter.
- 20 funds opened new Silence Therapeutics positions in Q2 2026 and 4 closed out, a net change of +16 holders.
- The largest Silence Therapeutics buyer in Q2 2026 was Soleus Capital Management, an estimated $4.43M added.
- The largest Silence Therapeutics seller in Q2 2026 was Nantahala Capital Management, an estimated $5.63M sold.
Based on aggregated 13F filings for Q2 2026.